Kadcyla is a medication that is used in the treatment of HER2-positive breast cancer. It is a combination of two drugs, trastuzumab and emtansine, which work together to target and destroy cancer cells. This medication is typically prescribed for patients who have already received treatment with trastuzumab and a taxane chemotherapy.

Kadcyla is administered through an intravenous infusion, usually once every three weeks. It is important to follow the dosing schedule provided by your healthcare provider to ensure the best possible outcome. Common side effects of Kadcyla may include nausea, fatigue, headache, and muscle pain. It is important to report any side effects to your healthcare provider so they can be properly managed.

As with any medication, there are risks and benefits associated with Kadcyla. Your healthcare provider will work with you to determine if this medication is the right choice for your individual situation. It is important to discuss any concerns or questions you may have about Kadcyla with your healthcare provider before starting treatment.

Overall, Kadcyla has been shown to be an effective treatment option for HER2-positive breast cancer. It is important to stay informed and engaged in your treatment plan to ensure the best possible outcome. Your healthcare provider is there to support you every step of the way and will work with you to address any concerns or questions you may have.